PT  - JOURNAL ARTICLE
AU  - Hou, Si-Yuan
AU  - Feng, Xing-Huo
AU  - Lin, Chang-Liang
AU  - Tan, Yong-Feng
TI  - Efficacy of Xuebijing for coagulopathy in patients with sepsis
AID  - 10.15537/smj.2015.2.9895
DP  - 2015 Jan 01
TA  - Saudi Medical Journal
PG  - 164--169
VI  - 36
IP  - 2
4099  - http://smj.org.sa/content/36/2/164.short
4100  - http://smj.org.sa/content/36/2/164.full
SO  - Saudi Med J2015 Jan 01; 36
AB  - Objectives: To provide evidence of the clinical efficacy of Xuebijing (XBJ) on blood coagulation in patients with sepsis.Methods: We conducted this meta-analysis in The People’s Hospital of Liaoning Province, Shenyang, China between December 2013 and May 2014. We searched a number of databases for relevant randomized controlled trials (RCTs) published before December 2013 using the keywords ‘Xuebijing’, ‘coagulation’ and ‘sepsis’. Statistical analysis was performed with Review Manager 5.2 from the Cochrane Collaboration.Results: Fourteen RCTs involving 867 patients were included. Compared with placebo, XBJ injection significantly improved platelets (mean differences [MD] = 42.14, 95% confidence interval [CI]: 22.42 - 61.86, p<0.00001), shortened the activated partial thromboplastin time (MD = -4.81, 95% CI: -7.86 - [-1.76], p=0.002), shortened the prothrombin time (MD = -2.33, 95% CI: -4.15 - [-0.51], p=0.01), and shortened the thrombin time (MD = -2.05, 95% CI: -3.52 - [-0.58], p=0.006). However, no significant difference was found between the XBJ injection and the placebo group for fibrinogen (MD = 0.21, 95% CI: -0.38 - 0.81, p=0.48).Conclusion: Xuebijing injection may improve coagulopathy in patients with sepsis. High-quality and large sample clinical trials are needed for confirmation.